In this upcoming live webinar, learn about how to use Artificial Intelligence (AI) to predict the efficacy of an investigational compound and identify the most relevant models to test. Attendees will gain insights about using AI to prioritize the most promising compounds and rank cancer types most likely to respond to a lead candidate. Certis Oncology Solutions' Director of Bioinformatics and Data Science, Long H. Do, PhD, will discuss employing machine learning (ML) technologies to identify predictive biomarkers and uncover relevant biological pathways indicative of drug mechanisms of action. Dr. Do will also discuss using AI to select optimal cancer models for in vitro and in vivo studies. Registered attendees will learn about using AI to project a compound's potential synergistic effects when combined with commercialized or investigational drugs.
TORONTO, April 25, 2023 /PRNewswire-PRWeb/ -- AI-enabled technologies are revolutionizing the drug development process, from target identification and lead optimization to early biomarker validation. By leveraging big data, bioinformatics and ML, cancer drug development and translational research teams can identify novel biomarkers, prioritize leads and make better informed preclinical decisions. Whether a strategy involves bringing novel cancer therapies to market or repurposing existing drugs, maximizing AI in cancer research can help unlock the full potential of candidate drugs and expedite the path to approval.
In this upcoming live webinar, Certis Oncology Solutions' Director of Bioinformatics and Data Science, Long H. Do, PhD, will explore how in silico innovations can bring new insights to oncology translational research and the drug development process.
AI in Cancer Research: Optimizing Biomarker Discovery, Model Selection, and Preclinical Decision-Making.
Tuesday, May 9, 2023, 2pm EDT (11am PDT)
For more information and to save your virtual seat, register now.
ABOUT CERTIS ONCOLOGY SOLUTIONS
Certis Oncology Solutions is a life science technology company committed to accelerating the development of new cancer therapies and realizing the promise of precision oncology. Our product is Oncology Intelligence™ — highly predictive therapeutic response data derived from advanced biological models of cancer and enhanced with AI-driven bioinformatics. Certis partners with therapeutics developers to help close the problematic translation gap between preclinical studies and clinical trials. Through more clinically relevant, well-characterized and annotated cancer models, advanced imaging technology, including x-ray irradiation with image-guided radiation therapy, and thoughtfully designed custom studies, our proprietary platform brings greater certainty to go/no-go drug development decisions.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: [email protected]
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected]
SOURCE Xtalks
Share this article